# Olema Pharmaceuticals, Inc.: financial statements, quarterly

OLMA · Nasdaq · CIK 1750284 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/olma.md) · [Financials](/companies/olma/financials.md) · [Filings](/companies/olma/filings.md) · [Insiders](/companies/olma/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/olma/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [19.5](/filings/0000950170-24-125427.md) | [25.9 d](/filings/0000950170-25-041204.md) | [29.9](/filings/0000950170-25-070374.md) | [29.1](/filings/0000950170-25-106565.md) | [33.2](/filings/0001193125-25-273236.md) | [32.3 d](/filings/0001193125-26-107169.md) | [30.6](/filings/0001193125-26-218156.md) | [43.9](/filings/0001193125-26-342383.md) | [40.0](/filings/0001193125-25-273236.md) | [43.2 d](/filings/0001193125-26-107169.md) | [49.2](/filings/0001193125-26-218156.md) | [57.8](/filings/0001193125-26-342383.md) |
| Operating income | $m | [(23.3)](/filings/0000950170-24-125427.md) | [(30.4) d](/filings/0000950170-25-041204.md) | [(34.3)](/filings/0000950170-25-070374.md) | [(33.5)](/filings/0000950170-25-106565.md) | [(37.6)](/filings/0001193125-25-273236.md) | [(36.8) d](/filings/0001193125-26-107169.md) | [(34.9)](/filings/0001193125-26-218156.md) | [(47.9)](/filings/0001193125-26-342383.md) | [(45.9)](/filings/0001193125-25-273236.md) | [(50.1) d](/filings/0001193125-26-107169.md) | [(58.0)](/filings/0001193125-26-218156.md) | [(67.2)](/filings/0001193125-26-342383.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(21.5)](/filings/0000950170-24-125427.md) | [(26.8) d](/filings/0000950170-25-041204.md) | [(31.0)](/filings/0000950170-25-070374.md) | [(30.4)](/filings/0000950170-25-106565.md) | [(34.6)](/filings/0001193125-25-273236.md) | [(33.6) d](/filings/0001193125-26-107169.md) | [(30.4)](/filings/0001193125-26-218156.md) | [(43.8)](/filings/0001193125-26-342383.md) | [(42.2)](/filings/0001193125-25-273236.md) | [(46.1) d](/filings/0001193125-26-107169.md) | [(53.1)](/filings/0001193125-26-218156.md) | [(63.2)](/filings/0001193125-26-342383.md) |
| Diluted EPS | $ per share | [(0.48)](/filings/0000950170-24-125427.md) | not reported | [(0.56)](/filings/0000950170-25-070374.md) | [(0.54)](/filings/0000950170-25-106565.md) | [(0.60)](/filings/0001193125-25-273236.md) | not reported | [(0.36)](/filings/0001193125-26-218156.md) | [(0.51)](/filings/0001193125-26-342383.md) | [(0.49)](/filings/0001193125-25-273236.md) | not reported | [(0.52)](/filings/0001193125-26-218156.md) | [(0.61)](/filings/0001193125-26-342383.md) |
| Basic EPS | $ per share | [(0.48)](/filings/0000950170-24-125427.md) | not reported | [(0.56)](/filings/0000950170-25-070374.md) | [(0.54)](/filings/0000950170-25-106565.md) | [(0.60)](/filings/0001193125-25-273236.md) | not reported | [(0.36)](/filings/0001193125-26-218156.md) | [(0.51)](/filings/0001193125-26-342383.md) | [(0.49)](/filings/0001193125-25-273236.md) | not reported | [(0.52)](/filings/0001193125-26-218156.md) | [(0.61)](/filings/0001193125-26-342383.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [117](/filings/0001558370-23-017994.md) | [68.5](/filings/0000950170-25-041204.md) | [33.7](/filings/0000950170-24-055686.md) | [16.9](/filings/0000950170-24-091836.md) | [35.9](/filings/0000950170-24-125427.md) | [139](/filings/0001193125-26-107169.md) | [50.6](/filings/0000950170-25-070374.md) | [52.5](/filings/0000950170-25-106565.md) | [35.3](/filings/0001193125-25-273236.md) | [48.3](/filings/0001193125-26-342383.md) | [52.5](/filings/0001193125-26-218156.md) | [48.6](/filings/0001193125-26-342383.md) |
| Current assets | $m | [282](/filings/0001558370-23-017994.md) | [267](/filings/0000950170-25-041204.md) | [252](/filings/0000950170-24-055686.md) | [242](/filings/0000950170-24-091836.md) | [218](/filings/0000950170-24-125427.md) | [438](/filings/0001193125-26-107169.md) | [397](/filings/0000950170-25-070374.md) | [368](/filings/0000950170-25-106565.md) | [334](/filings/0001193125-25-273236.md) | [515](/filings/0001193125-26-342383.md) | [513](/filings/0001193125-26-218156.md) | [470](/filings/0001193125-26-342383.md) |
| Total assets | $m | [293](/filings/0001558370-23-017994.md) | [277](/filings/0000950170-25-041204.md) | [264](/filings/0000950170-24-055686.md) | [255](/filings/0000950170-24-091836.md) | [230](/filings/0000950170-24-125427.md) | [451](/filings/0001193125-26-107169.md) | [410](/filings/0000950170-25-070374.md) | [382](/filings/0000950170-25-106565.md) | [352](/filings/0001193125-25-273236.md) | [533](/filings/0001193125-26-342383.md) | [531](/filings/0001193125-26-218156.md) | [487](/filings/0001193125-26-342383.md) |
| Current liabilities | $m | [16.0](/filings/0001558370-23-017994.md) | [21.6](/filings/0000950170-25-041204.md) | [26.2](/filings/0000950170-24-055686.md) | [26.5](/filings/0000950170-24-091836.md) | [30.7](/filings/0000950170-24-125427.md) | [41.8](/filings/0001193125-26-107169.md) | [26.1](/filings/0000950170-25-070374.md) | [33.2](/filings/0000950170-25-106565.md) | [41.7](/filings/0001193125-25-273236.md) | [51.8](/filings/0001193125-26-342383.md) | [47.2](/filings/0001193125-26-218156.md) | [53.0](/filings/0001193125-26-342383.md) |
| Total liabilities | $m | [17.7](/filings/0001558370-23-017994.md) | [23.1](/filings/0000950170-25-041204.md) | [27.4](/filings/0000950170-24-055686.md) | [27.4](/filings/0000950170-24-091836.md) | [31.3](/filings/0000950170-24-125427.md) | [42.0](/filings/0001193125-26-107169.md) | [26.2](/filings/0000950170-25-070374.md) | [36.8](/filings/0000950170-25-106565.md) | [45.0](/filings/0001193125-25-273236.md) | [54.9](/filings/0001193125-26-342383.md) | [50.2](/filings/0001193125-26-218156.md) | [56.0](/filings/0001193125-26-342383.md) |
| Shareholders' equity | $m | [275](/filings/0000950170-24-125427.md) | [254](/filings/0001193125-26-107169.md) | [236](/filings/0000950170-25-106565.md) | [227](/filings/0001193125-25-273236.md) | [199](/filings/0001193125-25-273236.md) | [409](/filings/0001193125-26-342383.md) | [383](/filings/0001193125-26-342383.md) | [345](/filings/0001193125-26-342383.md) | [307](/filings/0001193125-25-273236.md) | [479](/filings/0001193125-26-342383.md) | [480](/filings/0001193125-26-342383.md) | [431](/filings/0001193125-26-342383.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(22.7) d](/filings/0000950170-24-125427.md) | [(18.5) d](/filings/0000950170-25-041204.md) | [(23.5)](/filings/0000950170-25-070374.md) | [(27.6) d](/filings/0000950170-25-106565.md) | [(27.0) d](/filings/0001193125-25-273236.md) | [(26.3) d](/filings/0001193125-26-107169.md) | [(44.0)](/filings/0001193125-26-218156.md) | [(29.9) d](/filings/0001193125-26-342383.md) | [(34.5) d](/filings/0001193125-25-273236.md) | [(38.3) d](/filings/0001193125-26-107169.md) | [(46.0)](/filings/0001193125-26-218156.md) | [(45.9) d](/filings/0001193125-26-342383.md) |
| Capital expenditure | $m | not reported | not reported | [0.2](/filings/0000950170-25-070374.md) | [0.0 d](/filings/0000950170-25-106565.md) | [0.0 d](/filings/0001193125-25-273236.md) | [0.0 d](/filings/0001193125-26-107169.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-273236.md) | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.0](/filings/0001558370-23-017994.md) | [40.4](/filings/0000950170-24-055686.md) | [40.7](/filings/0000950170-24-091836.md) | [45.0](/filings/0000950170-24-125427.md) | [55.6](/filings/0000950170-25-070374.md) | [56.3](/filings/0000950170-25-106565.md) | [57.3](/filings/0001193125-25-273236.md) | [85.4](/filings/0001193125-26-218156.md) | [85.5](/filings/0001193125-26-342383.md) | [85.7](/filings/0001193125-25-273236.md) | [103](/filings/0001193125-26-218156.md) | [104](/filings/0001193125-26-342383.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 87,497,607 at 2026-08-06, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342383.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.